Radiolabeling Technique of Silver Nanoparticles (AgNPs) with Iodine-131 Radionuclide

U.N. Sholikhah, R.R. Syahdi, S.E. Permatasari, E. Sarmini, S Sriyono, T. Widyaningrum



Radiotherapy is an effective cancer therapy, where a certain dose of radiation is aimed specifically at target and is unaffecting to normal tissue. A selectiveradionuclide must be attached to the specific targeted organ. In this research, silver nanoparticles (AgNPs) were labeled with radionuclide of iodine-131 (131I) to be used in radiotherapy. Silver nanoparticles were synthesized using silver nitrate 0.0005 M, sodium borohydride 0.002 M, polyvinylpyrrolidone 0.3 % (w/v) and natrium chloride 1.5 M, and then followed by purification by centrifugation. Characterization was carried out with UV-Vis spectrophotometer, transmission electron microscope, particle size analyzer, and zeta-sizer. The results show that the maximum absorbance is on a wavelength of 398 nm, spherical shape with a diameter of 10 nm, polydispersity index of 0.455, and zeta potential value of –8 mV. The radiolabeling was done by adding sodium iodide-131 which had been oxidized by chloramine-T and immobilized in AgNPs colloidal solution, and the activity was then measured using a dose calibrator. The identification of radionuclide showed that the sample was free of impurities. The optimum system of radiochemical purity was obtained using Whatman 1 paper strip as the stationary phase and a mixture of methanol: water: ammonium acetate (1:1:1) as the mobile phase, which gave 96 % purity. This method is suitable for radiolabeling AgNPs with 131I to be used for radiotherapy.


Gamma counter; Radiochemical purity; Radionuclide purity; Radiotheraphy

Full Text:



M.E. Crestoni, Radiopharmaceuticals for Diagnosis and Therapy, in: Reference Module in Chemistry, Molecular Sciences and Chemical Engineering, Elsevier, United Kingdom (2018).

J. Mukiza, E. Byamukama, J. Sezirahiga et al., Rwanda Medical Journal 75 (2018) 14.

S.V. Gudkov, N.Y. Shilyagina, V.A. Vodeneev et al., Int. J. Mol. Sci. 17 (2016) 33.

A. Boschi, L. Uccelli and P. Martini, Appl. Sci. 9 (2019) 2526.

S. Chaturvedi and A.K. Mishra, Front. Med. 3 (2016) 1.

B. Khodashenas and H.R. Ghorbani, Arab. J. Chem. 12 (2019) 1823.

L. Farzin, S. Sheibani, M.E. Moassesi et al., J. Biomed. Mater. Res. 107 (2019) 251.

G. Bisht and S. Rayamajhi, Nanobiomedicine 3 (2016) 1.

A. Chrastina and J. E. Schnitzer, Int. J. Nanomedicine 5 (2010) 653.

H. Sadeghpour, M. Alavi, M. Shahedi et al., Trends in Pharmaceutical Sciences 1 (2015) 15.

Y. Khan, M. Qasimnasar, M. Numan et al., Int. J. Nanotechnol. Nanomed. 3 (2018) 1.

U.N. Sholikhah, A. Pujiyanto, E. Lestari et al., J. Pure App. Chem. Res. 5 (2016) 173.

S.E. Permatasari, 131I-Radiolabelled Silver Nanoparticle for Radiotheraphy, Undergraduate Thesis, University of Indonesia (2017). (in Indonesian).

S.V. Bannea, M.S. Patil, R.M. Kulkarnic et al., Materials Today: Proceedings 4 (2017) 12054.

C. Yen, H. Puigc, J.O. Tama et al., Lab. Chip. 15 (2015) 1638.

V. Sharma, D. Verma, and G.S. Okram, J. Phys.: Condens. Matter 32 (2020) 145302.

A.D. Kondorskiy, N.T. Lam and V.S. Lebedev, J. Russ. Laser Res. 39 (2018) 56.

S.S. Hinman, K.S. McKeating and Q. Cheng, Anal. Chem. 90 (2019) S1.

P. Roy, B. Das, A. Mohanty et al., Appl. Nanosci. 7 (2017) 843.

M. Negahdary, S. Omidi, A. Eghbali-Zarch et al., Biomedical Research 26 (2015) 794.

B. Neacsu, C. Cimpeanu and C. Barna, Romanian Reports in Physics 65 (2013) 155.

M. Klučáková, Front. Chem. 6 (2018) 1.

Anonymous, USP35 NF30: U.S. Pharmacopeia National Formulary, United States Pharmacopeia (2012).

Anonymous, European Pharmacopoeia, 8th Ed. Vol. 1, Council Europe (2013).


Copyright (c) 2020 Atom Indonesia

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.